No statistically significant difference in anti-cancer efficacy has been observed between tested oncolytic adenoviruses (Ad5/3-D24-ICOSL-CD40L vs. AdV5/3-D24) (Figures 2A, B). This evidence concerns the gene CD40LG and cancer.